LB Pharmaceuticals Inc. (LBRX) Maintains Buy Rating as Analyst Highlights LB-102 Potential

Published on July 2, 2026 at 4:06 pm by Laiba Immad in News

We recently compiled a list of the 8 Best Up and Coming Pharmaceutical Stocks to Buy Now. LB Pharmaceuticals Inc. (NASDAQ:LBRX) is one of the best up and coming stocks on our list.

TheFly reported on May 28 that Clear Street maintained a Buy rating and a $45 price target for LBRX. The firm stated that Neumora Therapeutics’ Phase 3 KOASTAL trial setback does not materially impact the outlook for LB-102. Clear Street highlighted that LB-102 is supported by established dopamine D2/D3 and serotonin 5-HT7 receptor activity, along with prior clinical evidence from related therapies. The firm also noted that LB-102 has shown strong Phase 2 results in schizophrenia and believes the company’s broader opportunities across schizophrenia, bipolar disorder, and major depressive disorder remain unchanged.

In addition to that, earlier on May 12, in its latest reported earnings for fiscal Q1 2026, LB Pharmaceuticals Inc. (NASDAQ:LBRX) provided a corporate update and reported financial results for the quarter ended March 31, 2026. Research and development expenses increased to $14.6 million, driven by higher clinical trial activity, manufacturing costs for LB-102, preclinical programs, and expanded personnel expenses. General and administrative expenses rose to $7.5 million due to increased staffing, stock-based compensation, and professional fees. The company reported a net loss of $19.1 million for the quarter. LB Pharmaceuticals ended the period with approximately $365.6 million in cash, cash equivalents, and marketable securities, expected to fund operations into Q2 2029.

LB Pharmaceuticals Inc. (NASDAQ:LBRX) is a late-stage biotech company developing neuropsychiatric therapies, including LB-102, a novel treatment candidate for schizophrenia, bipolar depression, and major depressive disorder.